Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2004
10/21/2004WO2004089912A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
10/21/2004WO2004089911A1 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer’s disease
10/21/2004WO2004089910A1 1,3,4-substituted pyrazoles for use as 5-ht receptor antagonists in the treatment of psychoses and neurological disorders
10/21/2004WO2004089909A1 2-azabicyclo[3.3.1]nonane derivatives as opioid receptor antagonists
10/21/2004WO2004089908A2 3-azabicyclo[3.2.1]octane derivatives
10/21/2004WO2004089905A1 N-[(piperazinyl)hetaryl]arylsulfonamide compounds with affinity for the dopamine d3 receptor
10/21/2004WO2004089897A1 Compounds having activity at 5ht2c receptor and uses thereof
10/21/2004WO2004089893A1 Substance exhibiting antidepressant property
10/21/2004WO2004089888A1 Pyrazole compounds
10/21/2004WO2004089882A2 Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
10/21/2004WO2004089876A1 Biphenylcarboxylic amide derivatives as p38 kinease inhibitors
10/21/2004WO2004089411A1 Remedy for spinal canal stenosis
10/21/2004WO2004089410A1 Preventive and/or remedy for neuropathic pain
10/21/2004WO2004089399A1 Novel uses of rfrp and ot7t022
10/21/2004WO2004089377A1 Calcium channel blockers comprising two benzhydril moieties
10/21/2004WO2004089375A1 Implantable polymeric device for sustained release of dopamine agonist
10/21/2004WO2004089373A1 4- (4-(heterocyclylalkoxy}phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer’s
10/21/2004WO2004089372A1 Substituted 4-phenyl-4-`1h-imidazol-2-yl !-piperidine derivatives and their use as selective non-peptide delta opioid agonists with antidepressant and anxiolytic activity
10/21/2004WO2004089371A1 Treatment of addiction
10/21/2004WO2004089370A1 4-phenyl-piperidine compounds and their use as modulators of opioid receptors
10/21/2004WO2004089369A2 Methods and means for treating protein conformational disorders
10/21/2004WO2004089366A1 Bicyclic compounds as nr2b receptor antagonists
10/21/2004WO2004089361A1 Therapeutic patch with polysiloxane matrix comprising capsaicin
10/21/2004WO2004089353A2 Methods for treatment of parkinson's disease
10/21/2004WO2004089352A2 Pharmaceutical combination for the treatment of spasticity and/or pain
10/21/2004WO2004089351A2 Treatment of progressive neurological disorders comprising a mao inhibitor (miclobemid) and an acetylcholinesterase inhibitor (tacrin)
10/21/2004WO2004089349A2 Use of an alpha2-adrenoceptor antagonist for the treatment of epilepsy
10/21/2004WO2004089313A2 Novel olanzapine forms and related methods of treatment
10/21/2004WO2004089312A2 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
10/21/2004WO2004072305A3 Atlastin
10/21/2004WO2004058287A8 Methods of treating neurological conditions with hematopoeitic growth factors
10/21/2004WO2004052389A3 Nogo, caspr, f3 nb-3 useful in the treatment of injury and disease to the central nervous system
10/21/2004WO2004052348A3 Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
10/21/2004WO2004014370A3 Oxadiazoles as modulators of metabotropic glutamate receptor-5
10/21/2004WO2004009556A9 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
10/21/2004WO2003096980A3 Bicyclic modulators of androgen receptor function
10/21/2004WO2003062241A8 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
10/21/2004WO2003045228A3 Methods for treating autoimmune disorders, and reagents related thereto
10/21/2004WO1995027066A9 Dna encoding ubiquitin conjugating enzymes
10/21/2004US20040210080 3-(oxo, oxime, hydrazone, or alkylidene)-fluorene derivatives; can be synergistically combined with other anticarcinogenic, anticholesterol, anxiolytic agents, antidepressants or enzyme inhibitors; bone disorders
10/21/2004US20040210079 selective monoamine oxidase B inhibitors; neurodegenerative diseases; Alzheimer's Disease
10/21/2004US20040210052 Efficient synthesis of 5-heteroatom-containing-pyrazoles
10/21/2004US20040210042 Polypeptides relating to signal transfer of advanced glycation end product receptor
10/21/2004US20040209959 X-Y, in which X is a benzyl group, a saturated or unsaturated cycloalkyl group or a non-cyclic, straight or branched alkyl group, optionally in combination with another analgesic, such as an NSAID or an opioid.
10/21/2004US20040209957 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke
10/21/2004US20040209955 preservative-free aqueous solution of sodium gamma-hydroxybutyrate, and a pH adjusting agent; pH of 6-7.5; chemically stable and resistant to microbial growth
10/21/2004US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
10/21/2004US20040209935 Pyrazole-derived kinase inhibitors and uses thereof
10/21/2004US20040209925 e.g., phenyl ((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(1S)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-hydroxypropyl)carbamate; inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide
10/21/2004US20040209914 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
10/21/2004US20040209909 in a carrier effective to permit sustained release at a therapeutically effective rate over an administration period of at least 8 hours
10/21/2004US20040209908 New derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments
10/21/2004US20040209906 Composition comprising ketanserin AND AN ALKANOYL L-CARNITINE FOR THE TREATMENT OF CRPS
10/21/2004US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors.
10/21/2004US20040209899 A2B adenosine receptor antagonists
10/21/2004US20040209894 e.g., 1-(4-chloroanilino)-4-[2-(pyridin-3-yl)-ethyl]-isoquinoline and 5-[4-(tert-butyl)-anilino]-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine
10/21/2004US20040209893 treatment of a condition mediated by a tachykinin including substance P and other neurokinins by administering N-benzyl-2-phenylpiperazine-1-carboxamides, e.g., 2-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic Acid (3,5-bistrifuoromethyl-benzyl)-methyl-amide Hydrochloride .
10/21/2004US20040209889 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
10/21/2004US20040209887 Pyrrolo[1,2-B]pyridazine compounds and their uses
10/21/2004US20040209883 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors
10/21/2004US20040209879 Piperidinyl derivates as modulators of chemokine receptor activity
10/21/2004US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
10/21/2004US20040209872 Calcium channel blockers comprising two benzhydril moieties
10/21/2004US20040209870 contain 5-HT ligands used to treat central nervous system disorders
10/21/2004US20040209868 Substituted indoles
10/21/2004US20040209867 for treatment of disorders (sleeping, feeding) relating to or affected by the 5-HT6 receptor; serotonin receptor antagonists
10/21/2004US20040209861 Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
10/21/2004US20040209856 Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation
10/21/2004US20040209817 Methods and compositions for the treatment of peripheral artery disease
10/21/2004US20040209813 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases
10/21/2004US20040209810 administering transforming/nerve growth factors to putamen via catheter connected to inflatable pump; increasing dopaminergic neurons; drug delivery kits
10/21/2004US20040209798 biodrugs for treatment of lung cancer, glioma, anorexia, hypothyroidism, hyperaldosteronism, H. pylori proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites
10/21/2004US20040209308 Methods of assaying receptor activity and constructs useful in such methods
10/21/2004US20040208941 Compositions for removal of toxins
10/21/2004US20040208938 for needles comprising time release microparticles containing risperidones, glycolic acid-lactic acid copolymer binders, and high viscosity aqueous fluids (containing sodium carboxymethyl cellulose as modifier)
10/21/2004US20040208927 Process for preparing non-hygroscopic sodium valproate composition
10/21/2004US20040208924 active pharmaceutical ingredient is for example [(2S)-Sulfanyl-5-[(N,N-dimethylamino)acetyl]aminopentanoyl-L-leucyl-L-tert-leucine N-methylamide; bonding strength, stability
10/21/2004US20040208923 administering a therapeutically effective amount of a pharmacologic agent that enhances learning or conditioning within 24 hours prior to conducting session of psychotherapy
10/21/2004US20040208889 Pharmaceutical use for secreted bacterial effector proteins
10/21/2004CA2523186A1 Method of screening drug with the use of 67 kda laminin receptor and drug obtained thereby
10/21/2004CA2522214A1 4-phenyl-piperidine compounds and their use as modulators of opioid receptors
10/21/2004CA2521907A1 Bicyclic compounds as nr2b receptor antagonists
10/21/2004CA2521899A1 4- (4-(heterocyclylalkoxy}phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases suchas alzheimer's
10/21/2004CA2521875A1 Calcium channel blockers comprising two benzhydril moieties
10/21/2004CA2521656A1 Treatment of epilepsy
10/21/2004CA2521653A1 Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
10/21/2004CA2521340A1 Aminopyrimidine derivatives and their medical use
10/21/2004CA2521202A1 1,3,4-substituted pyrazoles for use as 5-ht receptor antagonists in the treatment of psychoses and neurological disorders
10/21/2004CA2521201A1 Substituted pyrazoles for use in the prophylaxis or treatment of a disease which can be influenced by the binding of the substitued pyrazoles to 5ht receptors
10/21/2004CA2521199A1 Pyrazole compounds
10/21/2004CA2521186A1 Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists with antidepressant and anxiolytic activity
10/21/2004CA2521000A1 Preventive and/or therapeutic agent for neuropathic pain
10/21/2004CA2520855A1 Imidazopyridine derivatives as melanocortin receptor agonists
10/21/2004CA2518916A1 Pi-3 kinase inhibitor prodrugs
10/21/2004CA2517833A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
10/20/2004EP1468999A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
10/20/2004EP1468996A1 Indole derivatives for the treatment of CNS disorders
10/20/2004EP1468995A1 MPTP affinity labels
10/20/2004EP1468990A1 Piperazine derivative
10/20/2004EP1468689A1 2-methyl-thieno-benzodiazepine formulation
1 ... 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 ... 1833